Deep Dive · rNPV Rank 07Grant / non-commercial

PUMA Mediates the Apoptotic Response to p53

Generated by an autonomous AI research agent — Anthropic Claude Opus 4.7 or OpenAI GPT-5.5, max reasoning effort. Sources cited inline. Full disclosure at /methodology/jhtv-deep-dive.

Indication

cancer (p53 pathway apoptosis)

Modality

Gene Therapy

Mechanism

PUMA / p53 apoptosis pathway activator

Target

TP53

rNPV Envelope

Low

-$15.8M

costs +25% · peak −25%

Base

-$12.5M

cumulative PoS 0.4%

High

-$9.3M

costs −25% · peak +25%

This is an illustrative p53-pathway gene-therapy envelope only because the pipeline requires stages. The actual asset is a basic-science PUMA/p53 apoptosis finding; PoS is therefore materially lower than a defined adenoviral p53 product.

01

Composite score breakdown

Locked rubric — 40/30/30 weights

Clinical relevance · 40%

0.50

Modality fit · 30%

0.74

Whitespace · 30%

0.50

Composite 0.572 — composite-score rank #41 of 50 top-tier inventions in the jhtv-portfolio@2026-Q2 cohort. The page header uses rNPV rank (#7) to match the index ordering.

02

Comparators

Real programs anchoring the engine inputs

PUMA / BBC3 p53-apoptosis discovery

The direct asset: PUMA as a p53-induced mediator of apoptosis. It is a mechanistic finding in cancer biology, not a gene-therapy candidate.

Indication: Cancer biology / p53 pathway
Modality: Basic-science discovery
Approval:
Peak revenue:

Criteria 1: exact mechanism; not a drug comparator.

Gendicine / rAd-p53

Closest p53-pathway gene-therapy archetype: an adenoviral p53 product approved in China for head and neck cancer. It anchors what an actual p53 gene-therapy product would look like, but it is not PUMA.

Indication: Head and neck squamous cell carcinoma
Modality: Adenoviral p53 gene therapy
Approval: 2003
Peak revenue:

Criteria 3 and 4: p53-pathway regulatory archetype; not same target/product.

p53-based cancer therapy literature

Adjacent therapeutic context showing that p53 pathway restoration can be productized only when a defined vector/drug exists.

Indication: Solid tumors
Modality: Gene therapy / pathway restoration
Approval:
Peak revenue:

Criteria 1 and 4: same pathway, different product reality.

03

Stage profile

Asset-specific cost, duration, and PoS by stage

StageCostDurationPoSCitations
Preclinical$5.0M18 mo22.0%[0] [1]
Phase I$22.0M18 mo46.0%[1] [2]
Phase II$70.0M30 mo17.0%[1] [2]
Phase III$170.0M42 mo32.0%[2] [3]
NDA/BLA Review$12.0M12 mo80.0%[2]

Multiplier handling: No multipliers eligible for this asset under the locked methodology. See methodology for the rule.

04

Peak revenue and discount rate

$50.0M peak · WACC 16.0%

Peak revenue. The current asset has no drug substance or proprietary product peak. The $50M illustrative figure reflects possible grant, reagent, or follow-on licensing value if separately productized, not a cancer-therapy revenue forecast.

WACC. Basic cancer-biology discovery without a defined therapeutic modality has very high translation risk and low standalone commercial relevance.

05

Sensitivity (tornado)

Top drivers of rNPV variance

PoS: Preclinical
18%26%
-$10.9M
-$14.1M
$3.2M
Cost: Preclinical
$4M$7M
-$11.2M
-$13.9M
$2.7M
Cost: Phase II
$49M$91M
-$11.4M
-$13.7M
$2.3M
Cost: Phase I
$15M$29M
-$11.5M
-$13.6M
$2.1M
PoS: Phase I
37%55%
-$11.6M
-$13.5M
$1.8M
WACC
13%19%
-$13.4M
-$11.8M
+$1.6M

Drivers ranked by absolute rNPV swing. The vertical tick inside each bar marks the base rNPV (-$12.5M); each bar spans the rNPV range produced by flexing one input between its low and high values. Gold = the input pushes rNPV up when increased; red = the input pushes rNPV down when increased.

06

Monte Carlo distribution

1,000 trials · rpNPV mode

Failure cluster · 100.0% of paths
$0 ↓
Success tail · 0.0% of paths
P50 medianBase rNPV (mean)-$251.8MeNPV outcome bin (sqrt-scaled height)-$618K

This is a bimodal distribution by construction, not a Gaussian. Most paths terminate in clinical failure (red cluster — accumulated cost only); a minority succeed and capture full peak revenue (green tail). Bar heights are square-root-scaled so the success tail stays visible alongside the much taller failure cluster; exact counts are preserved in the percentiles below. Gold line = median (P50). Navy dashed = base rNPV (mean) — the probability-weighted expected value, which can sit above the median when the upper tail is strong enough to outweigh the failure cluster (and close to the median when it isn’t).

P5

-$63.3M

P25

-$10.7M

P50 (median)

-$4.7M

P75

-$3.1M

P95

-$1.7M

Prob ≥ 0

0.0%

07

Evidence register

4 per-assumption citations

AssumptionSourceDateConfidence
JHU asset is PUMA/p53 pathway biology
cmo_findings.asset_class_reality
PUMA Mediates the Apoptotic Response to p53
regulatory
2014-10-07high
Original PUMA discovery
comparators[0]
PUMA, a Novel Proapoptotic Gene, Is Induced by p53
peer_review
2001-03-01high
p53 gene therapy product archetype
comparators[1]
The First Approved Gene Therapy Product for Cancer Ad-p53 (Gendicine): 12 Years in the Clinic
peer_review
2018-01-01high
Clinical p53 pathway context
stage_profile.phase_3.pos
Expert consensus on recombinant adenovirus human p53 for head and neck cancers
peer_review
2021-09-24medium
08

Thesis

Why this asset earns its rank

This is a basic-science finding, not a therapeutic asset. The invention points to PUMA/BBC3 as a mediator of p53-dependent apoptosis in cancer cells; that matters scientifically, but it is not a vector, molecule, antibody, or drug candidate. The rNPV envelope is shown only for cohort consistency - the rNPV is not the decision criterion here, which is why the asset is classified grant_non_commercial.

The closest product comparator is not PUMA; it is Gendicine, an adenoviral p53 gene-therapy product approved in China. That comparator shows what a real p53-pathway therapy looks like only after the biology is embedded in a specific vector and indication. The engine result is -$15.8M to -$9.3M, with a base rNPV of -$12.5M and cumulative PoS of 0.4%; that placeholder should not be read as PUMA-product value because no such product exists in the asset file.

Verdict: important biology, non-commercial at this stage. It earns its rank because the p53 pathway is clinically central and the gene_therapy bucket is powerful in the rubric, but a CMO would reject any manufactured PUMA drug DCF.

09

Key risks

Asset-specific, not generic biotech risks

  • Asset-class mismatch: PUMA mediating p53 apoptosis is a discovery, not a product candidate.
  • No modality: the asset file does not specify gene delivery, peptide mimicry, small molecule, or any drug-like intervention.
  • P53-pathway complexity: tumors frequently disable p53 upstream or downstream, so simply invoking PUMA does not define a therapeutic window.
  • Commercial moat risk: follow-on productization would need new IP around an actual modality, not just the historic pathway finding.